And the starting doses, while lower, are being injected into tissue that has not adapted to regular subcutaneous medication administration
Bnh h thn kinh: Ngoi cc lnh vc trn, thuc GLP-1 cn c s dng rng ri trong iu tr cc bnh thn kinh, chng hn nh bnh Alzheimer, bnh Parkinson v t qu
Reported side effects are usually mild
CV risk profile subgroups To assess the effect of baseline CV risk profiles on outcomes, two separate subgroup analyses were performed: (1) for subjects who had experienced a prior MI or stroke compared with those who had not, and (2) for those with established CVD, defined as prior stroke, ischemic heart disease (including MI), peripheral arterial disease, 50% arterial stenosis in any artery, coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft), or heart failure vs those with CV risk factors alone and no manifestations of CVD as defined above
Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G